Tech Company Financing Transactions
Star Therapeutics Funding Round
Star Therapeutics closed a $90 million Series C funding round on 9/5/2023. Investors included Agent Capital, Catalio Capital Management and Cormorant Asset Management.
Transaction Overview
Company Name
Announced On
9/5/2023
Transaction Type
Venture Equity
Amount
$90,000,000
Round
Series C
Investors
Proceeds Purpose
The company intends to use the funds for clinical advancement of VGA039, a first-in-class antibody currently being evaluated in a Phase 1a/1b study for von Willebrand disease. This novel therapy is being developed by Vega Therapeutics, a Star portfolio company focused on underserved blood disorders. Proceeds will also be used to continue Star's approach as an innovation engine to generate additional biotech companies focused on discovering and advancing novel antibody therapies, each targeting multiple diseases.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
201 Haskins Way, 5th Floor South
San Francisco, CA 94080
USA
San Francisco, CA 94080
USA
Phone
Website
Email Address
Overview
Our mission is to develop life-changing therapies for as many rare diseases as possible for the millions of patients in urgent need. Medical science has identified approximately 7,000 rare diseases. Individually, these conditions may impact few patients. Together, however, they affect approximately 30 million patients in the US alone, and 300 million worldwide.1-3 Although these diseases affect so many, only about 650 FDA-approved treatments have been developed to target them.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Adam Rosenthal
Chief Marketing Officer
Gary Patou
Chief Operating Officer
Kathy Dong
Chief Scientific Officer
Sandip Panicker
Browse more venture capital transactions:
Prev: 9/5/2023: Tribun Health venture capital transaction
Next: 9/5/2023: ViAqua Therapeutics venture capital transaction
Share this article
About Our Venture Capital Transactions Database
Our team works diligently to report on every notable VC transaction. All VC database entries reported here are sourced from company press releases and news coverage. The information is sourced from VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs